Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats.

Cancer Chemother Pharmacol

Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd., Rm. 2116, Bethesda, MD 20892, USA.

Published: May 2012

Purpose: CP-31398 (N0-[2-[(E)-2-(4-methoxyphenyl)ethenyl] quinazolin-4-yl]-N,N-dimethylpropane-1,3-diamine hydrochloride) is one of the new class of agents that can stabilize the DNA-binding domain of p53 and thereby maintain the activity of p53 as a tumor suppressor and transcription factor. Through its activity as a p53 stabilizer, CP-31398 demonstrates significant cancer preventive and therapeutic activity in several in vivo animal models. The objective of the current study was to describe the pharmacokinetic profile and tissue distribution of this novel agent following intravenous or oral (gavage and dietary) administration.

Methods: CP-31398 was administered to male CD and F344 rats as a single intravenous bolus dose or by daily oral gavage dosing. Male F344 rats also received drug as an ad libitum dietary supplement. Plasma, liver, skin, colon, and colon tumor samples were collected after oral dosing. Concentrations of CP-31398 in plasma and tissue samples were analyzed using LC–MS/MS, and the resultant data were subjected to a non-compartmental pharmacokinetic analysis.

Results: Bioavailability (12–32%), elimination half-life (14–20 h), clearance (4.2–4.8 l/h/kg), and volume of distribution (70–82 l/kg) were determined. Tissue levels of CP-31398 after oral (gavage or diet) administration were several orders of magnitude higher than were corresponding plasma concentrations; CP-31398 levels were especially high in colon and liver. Levels of CP-31398 in tissues were higher after gavage dosing than after dietary administration.

Conclusions: CP-31398 is bioavailable and has a relatively long elimination half-life, which supports the achievement of plasma steady-state levels with a once daily dosing regimen. CP-31398 exhibits a dramatically high volume of distribution, which is consistent with its tissue concentrations being much higher than corresponding plasma levels. It is accumulated in colon tumor tissues, albeit at lower concentrations than found in liver, skin, and colon.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1811-9DOI Listing

Publication Analysis

Top Keywords

oral gavage
12
cp-31398
10
activity p53
8
male f344
8
f344 rats
8
gavage dosing
8
liver skin
8
skin colon
8
colon tumor
8
concentrations cp-31398
8

Similar Publications

Preparation and Hypoglycemic Effect of Magnolia Officinalis Polysaccharide Oral Liquid.

Plant Foods Hum Nutr

January 2025

Hubei Key Laboratory of Biologic Resources Protection and Utilization, Hubei Minzu University, Enshi, 445000, P.R. China.

In this paper, an oral liquid containing Magnolia officinalis polysaccharide was formulated and its hypoglycemic effects were investigated. An orthogonal test was conducted based on single-factor experiments to optimize the formulation guided by sensory evaluations. Its stability and safety were also assessed.

View Article and Find Full Text PDF

Acetylcarvacrol is a semi-synthetic product derived from carvacrol and has known activity against ticks. In vertebrates, the thyroid has been used as a bioindicator in toxicity studies due to its sensitivity to external factors. Thus, the objective of this study was to evaluate the toxic effects of acetylcarvacrol in Wistar rats subjected to repeated dose dermal and oral toxicity tests by means of histopathological analysis of the thyroid.

View Article and Find Full Text PDF

Protocol for fecal microbiota transplantation: A microaerophilic approach for mice housed in a specific pathogen-free facility.

STAR Protoc

January 2025

Microbiology & Radiobiology Units, Belgian Nuclear Research Centre SCK CEN, 2400 Mol, Belgium; Bioinformatics Group, Center for Informatics Science, Nile University, Giza, Egypt. Electronic address:

Recently, studies have emerged exploring the potential application of fecal microbiota transplantation (FMT) in pre-clinical settings. Here, we present a protocol for FMT for mice housed in a specific pathogen-free (SPF) facility. We describe steps for sample collection, microaerophilic processing of freshly collected fecal pellets, and administration through oral gavage.

View Article and Find Full Text PDF

Oral Delivery of miR146a Conjugated to Cerium Oxide Nanoparticles Improves an Established T Cell-Mediated Experimental Colitis in Mice.

Pharmaceutics

December 2024

Laboratory for Fetal and Regenerative Biology, Department of Surgery, University of Arizona Tucson College of Medicine, Banner Children's at Diamond Children's Medical Center, 1656 E Mabel St, Rm 230, Tucson, AZ 85721, USA.

Dysregulated inflammation and oxidative stress are strongly implicated in the pathogenesis of inflammatory bowel disease. We have developed a novel therapeutic that targets inflammation and oxidative stress. It is comprised of microRNA-146a (miR146a)-loaded cerium oxide nanoparticles (CNPs) (CNP-miR146a).

View Article and Find Full Text PDF

: Cannabidiol (CBD) is an approved treatment for childhood epilepsies and a candidate treatment for several other CNS disorders. However, it has poor oral bioavailability. We investigated the effect of a novel lipid formulation on its absorption in humans and on its tissue distribution in mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!